Literature DB >> 28644184

Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.

Christopher Ma1, Rowan Lumb, Emily V Walker, Rae R Foshaug, ThucNhi T Dang, Sanam Verma, Vivian W Huang, Karen I Kroeker, Karen Wong, Levinus A Dieleman, Richard N Fedorak, Brendan P Halloran.   

Abstract

BACKGROUND: The noninvasive biomarkers fecal immunochemical testing (FIT) and fecal calprotectin (FCP) are sensitive for prediction of mucosal inflammation in inflammatory bowel disease. However, neither test has yet been shown to independently and accurately predict mucosal healing (MH). We aimed to assess the specificity of noninvasive FIT and FCP for MH prediction.
METHODS: In this prospective cohort study of adult inflammatory bowel disease outpatients presenting for colonoscopy, stool samples for FIT and FCP were collected 48 hours before endoscopy. Using MH defined by Simple Endoscopic Score for Crohn's disease (SES-CD = 0), Rutgeert's score (i0), and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS = 3), receiver operator characteristic curves were plotted, and sensitivity, specificity, positive and negative predictive values, and areas under the curve were calculated. Multivariate logistic regression analysis was used to develop a clinical model for noninvasively predicting MH.
RESULTS: Eighty patients (40 Crohn's disease and 40 ulcerative colitis) were enrolled. The specificities of FIT <100 ng/mL and FCP <250 μg/g for MH were 0.57 (95% confidence interval, 0.38-0.74) and 0.77 (0.57-0.89), respectively. Positive predictive values for MH for FIT <100 ng/mL and FCP <250 μg/g were 0.78 (0.64-0.87) and 0.77 (0.58-0.90), respectively. In multivariate modeling, combining FIT, FCP, and clinical symptomatic remission improved specificity for MH to 0.90 (0.72-0.97) with positive predictive values of 0.84 (0.60-0.96). Areas under the curve for FIT was higher for patients with ulcerative colitis (0.88) than for patients with Crohn's disease (0.69, P = 0.05).
CONCLUSIONS: FIT and FCP have similar performance characteristics for identifying MH. Combined, low FIT, low FCP, and clinical remission are specific for MH.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28644184     DOI: 10.1097/MIB.0000000000001173

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  13 in total

1.  Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Bing-Jie Xiang; Min Jiang; Ming-Jun Sun; Cong Dai
Journal:  Visc Med       Date:  2021-01-21

2.  Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis: a retrospective cohort analysis.

Authors:  Hsu-Heng Yen; Mei-Wen Chen; Yu-Yao Chang; Hsuan-Yuan Huang; Tsui-Chun Hsu; Yang-Yuan Chen
Journal:  PeerJ       Date:  2020-07-14       Impact factor: 2.984

3.  Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis.

Authors:  William A Bye; Christopher Ma; Tran M Nguyen; Claire E Parker; Vipul Jairath; James E East
Journal:  Am J Gastroenterol       Date:  2018-10-23       Impact factor: 10.864

4.  Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.

Authors:  Parambir S Dulai; Robert Battat; Maria Barsky; Nghia H Nguyen; Christopher Ma; Neeraj Narula; Mahmoud Mosli; Niels Vande Casteele; Brigid S Boland; Larry Prokop; M Hassan Murad; Geert D'Haens; Brian G Feagan; William J Sandborn; Vipul Jairath; Siddharth Singh
Journal:  Am J Gastroenterol       Date:  2020-06       Impact factor: 12.045

5.  Fecal Immunochemical Test and Fecal Calprotectin Measurement Are Noninvasive Monitoring Tools for Predicting Endoscopic Activity in Patients with Ulcerative Colitis.

Authors:  Ji Young Chang; Jae Hee Cheon
Journal:  Gut Liver       Date:  2018-03-15       Impact factor: 4.519

6.  Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study.

Authors:  Shiro Nakamura; Hirotsugu Imaeda; Hiroki Nishikawa; Masaki Iimuro; Minoru Matsuura; Hideo Oka; Junsuke Oku; Takako Miyazaki; Hirohito Honda; Kenji Watanabe; Hiroshi Nakase; Akira Andoh
Journal:  Intest Res       Date:  2018-10-10

7.  Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis.

Authors:  Dae Gon Ryu; Hyung Wook Kim; Su Bum Park; Dae Hwan Kang; Cheol Woong Choi; Su Jin Kim; Hyeong Seok Nam
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

8.  Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease.

Authors:  Lung-Yi Mak; Teresa S M Tong; Ka-Shing Cheung; Li-Jia Chen; Ka-Luen Lui; Kam-Shing Lau; Wai K Leung
Journal:  Clin Transl Gastroenterol       Date:  2020-03       Impact factor: 4.396

9.  Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease.

Authors:  Eriko Yasutomi; Toshihiro Inokuchi; Sakiko Hiraoka; Kensuke Takei; Shoko Igawa; Shumpei Yamamoto; Masayasu Ohmori; Shohei Oka; Yasushi Yamasaki; Hideaki Kinugasa; Masahiro Takahara; Keita Harada; Masaki Furukawa; Kouichi Itoshima; Ken Okada; Fumio Otsuka; Takehiro Tanaka; Toshiharu Mitsuhashi; Jun Kato; Hiroyuki Okada
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

10.  Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study.

Authors:  Lorenzo Bertani; Corrado Blandizzi; Maria Gloria Mumolo; Linda Ceccarelli; Eleonora Albano; Gherardo Tapete; Giovanni Baiano Svizzero; Federico Zanzi; Francesca Coppini; Nicola de Bortoli; Massimo Bellini; Riccardo Morganti; Santino Marchi; Francesco Costa
Journal:  Clin Transl Gastroenterol       Date:  2020-05       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.